1. Home
  2. SKWD vs IMNM Comparison

SKWD vs IMNM Comparison

Compare SKWD & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Skyward Specialty Insurance Group Inc.

SKWD

Skyward Specialty Insurance Group Inc.

HOLD

Current Price

$60.11

Market Cap

2.2B

Sector

Finance

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$22.76

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SKWD
IMNM
Founded
2007
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.6B
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
SKWD
IMNM
Price
$60.11
$22.76
Analyst Decision
Buy
Strong Buy
Analyst Count
8
10
Target Price
$64.63
$32.80
AVG Volume (30 Days)
705.2K
1.7M
Earning Date
05-06-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
41.81
51.40
EPS
1.09
N/A
Revenue
$1,416,541,000.00
$6,941,000.00
Revenue This Year
$29.54
N/A
Revenue Next Year
$12.64
$1,127.34
P/E Ratio
$55.70
N/A
Revenue Growth
23.16
N/A
52 Week Low
$40.60
$8.67
52 Week High
$63.03
$27.65

Technical Indicators

Market Signals
Indicator
SKWD
IMNM
Relative Strength Index (RSI) 61.60 56.82
Support Level $43.19 $19.28
Resistance Level $63.03 $23.25
Average True Range (ATR) 2.20 1.35
MACD -0.39 -0.08
Stochastic Oscillator 57.97 47.24

Price Performance

Historical Comparison
SKWD
IMNM

About SKWD Skyward Specialty Insurance Group Inc.

Skyward Specialty Insurance Group Inc is a specialty insurance company that offers a suite of specialized insurance solutions across specialty property and casualty markets on a non-admitted and admitted basis. Its portfolio of insurance offerings covers a wide variety of risks, including general liability, commercial auto, group accident and health, property, agriculture, credit, surety, and workers' compensation, among others. Geographically, the group mainly operates in the United States.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: